Statistics
The Aprea Therapeutics stock price is currently $ 0.4162 with a total market cap valuation of $ 5.91M (14.19M shares outstanding). The Aprea Therapeutics is trading on NASDAQ under the ticker sign APRE. Aprea Therapeutics price is up
Description
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Company Profile
- Full Name: Aprea Therapeutics
- Sector: Healthcare
- Website: https://atrinpharma.com
